[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Chen P, Hu WM, Wang PH, Suen JH: Recurrent breast cancer presents as a single solid ovarian mass and ascites. Taiwan J Obstet Gynecol; 2006 Dec;45(4):356-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent breast cancer presents as a single solid ovarian mass and ascites.
  • However, aside from the primary origin, a metastatic lesion should be considered, since the ovary is frequently metastasized from cancers of other organs, such as the genital tract, gastrointestinal tract, and breast.
  • CASE REPORT: A 47-year-old woman with a history of right breast infiltrating lobular carcinoma, T3N0M0, grade 3, was treated with modified radical mastectomy and axillary lymph-node dissection in July 2001.
  • Therefore, she underwent palliative radiotherapy and various kinds of chemotherapy.
  • However, metastatic carcinoma of the ovary of breast origin was finally diagnosed.
  • [MeSH-major] Ascites / etiology. Breast Neoplasms / pathology. Carcinoma / secondary. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175500.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP Jr: A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res; 2002 Mar;8(3):691-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
  • DESIGN: A Phase I study was conducted to evaluate sequential treatment with bolus IV doxorubicin followed 48 h later by topotecan given as a 30-min i.v. infusion on 3 consecutive days, with additional cycles of therapy repeated every 3 weeks.
  • All patients had received prior therapy (median >or=2 prior regimens).
  • The partial responses occurred in patients with small cell lung cancer (3 of 7), non-small cell lung cancer (1 of 6), esophageal adenocarcinoma (1 of 2), and ovarian carcinoma (1 of 1), and it lasted for 3-6 months.
  • Changes in topoisomerase mRNA levels were observed during chemotherapy.
  • CONCLUSIONS: The sequential combination of doxorubicin followed by topotecan is highly active in several chemotherapy refractory long, ovary, and esophageal cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm. Area Under Curve. DNA Primers / metabolism. DNA Topoisomerases, Type I / genetics. DNA Topoisomerases, Type I / metabolism. DNA Topoisomerases, Type II / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / pharmacokinetics. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. RNA, Messenger / metabolism. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Safety. Topotecan / administration & dosage. Topotecan / adverse effects. Topotecan / pharmacokinetics. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11895897.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; EC 5.99.1.3 / DNA topoisomerase II beta
  •  go-up   go-down


3. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography showed an 18 x 16 cm right pelvic tumor, with both cystic and solid components, ascites and bilateral massive pleural effusion.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Adjuvant chemotherapy with carboplatin and paclitaxel was prescribed postoperatively, but the malignancy was not controlled due to lung, brain and vulva metastases.
  • CONCLUSION: The coexistence of primary neoplasms in the ovary and cervix is rare.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Carcinoembryonic Antigen / metabolism. Combined Modality Therapy. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Necrosis. Vulvar Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175478.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


Advertisement
4. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH: Malignant transformation of mature cystic teratoma of the ovary: experience at a single institution. Eur J Obstet Gynecol Reprod Biol; 2008 Dec;141(2):173-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of mature cystic teratoma of the ovary: experience at a single institution.
  • OBJECTIVES: Malignant transformation of mature cystic teratoma (MCT) of ovary is very rare.
  • Therefore, the clinicopathologic characteristics, treatment and prognostic factors are not yet well established.
  • Squamous cell carcinoma was the most common histologic type, comprising 75%.
  • Twelve patients had some solid portions in the cyst containing fat fluid, hair, and/or calcification.
  • According to the review of the patients in our study and of the literature, early detection and complete surgical resection are important for long-term survival.
  • It seems that adjuvant chemotherapy or concurrent chemoradiation therapy have roles in treating this malignancy.
  • CONCLUSIONS: Early detection is important for long-term survival.
  • Old age, large tumor size, and solid portion in mature cystic teratoma seem to predict the malignant transformation of mature cystic teratoma.
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / pathology. Female. Humans. Incidence. Korea / epidemiology. Middle Aged. Parity. Pregnancy. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18823690.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


5. Okada S, Ohaki Y, Inoue K, Nakajo H, Kawamata H, Kumazaki T: A case of dermoid cyst of the ovary with malignant transformation complicated with small intestinal fistula formation. Radiat Med; 2005 Sep;23(6):443-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of dermoid cyst of the ovary with malignant transformation complicated with small intestinal fistula formation.
  • CT showed a huge gas-containing cystic mass with fatty component and solid structure.
  • Emergency surgery was performed, and an enlarged left ovary that was adherent to the small intestine was removed.
  • Microscopic examination revealed a squamous cell carcinoma in the dermoid cyst wall.
  • The carcinoma had directly invaded the small intestine and a fistula between the cyst and the intestine was noted.
  • Thickened omentum showed granulomatous inflammation in the fatty tissue, but no metastases were detected.
  • The histopathological diagnosis was dermoid cyst with malignant transformation and invasion of the small intestine.
  • Chemotherapy was performed, but the patient died of progression of peritoneal metastases 10 months after the operation.
  • [MeSH-major] Carcinoma, Squamous Cell / radiography. Cell Transformation, Neoplastic. Dermoid Cyst / radiography. Intestinal Fistula / radiography. Ovarian Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16389989.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Sant'Ambrogio S, Malpica A, Schroeder B, Silva EG: Primary ovarian rhabdomyosarcoma associated with clear cell carcinoma of the ovary: a case report and review of the literature. Int J Gynecol Pathol; 2000 Apr;19(2):169-73
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian rhabdomyosarcoma associated with clear cell carcinoma of the ovary: a case report and review of the literature.
  • The clinicopathologic and immunohistochemical findings of a case of coexistent primary ovarian rhabdomyosarcoma and clear cell carcinoma of the ovary are reported.
  • The tumor was composed of solid and cystic areas, and two distinct microscopic components were identified: clear cell carcinoma and rhabdomyosarcoma.
  • Despite two cycles of chemotherapy, the disease persisted in the pelvis 4 months after diagnosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis. Rhabdomyosarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10782415.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / Myoglobin
  • [Number-of-references] 13
  •  go-up   go-down


7. Fujiwara K, Maehata K, Kohno I, Yoden E, Imajo Y, Mikami Y: [A case of clear cell carcinoma of the ovary responding to a paclitaxel-carboplatin combination chemotherapy]. Gan To Kagaku Ryoho; 2000 Dec;27(14):2259-62
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of clear cell carcinoma of the ovary responding to a paclitaxel-carboplatin combination chemotherapy].
  • Clear cell carcinoma of the ovary is believed to be chemoresistant; therefore, choosing anticancer agents is often difficult.
  • In this report we present a case of ovarian clear cell carcinoma that showed a significant response to a combination chemotherapy with paclitaxel and carboplatin.
  • The patient is a 51-year-old Japanese female with a history of Gn-RH treatment for endometriosis that was terminated three years before the presentation of this disease.
  • The initial surgery revealed the tumor was a clear cell carcinoma of the left ovary, showing a predominantly solid growth pattern as well as papillary and tubular patterns.
  • Combination chemotherapy using paclitaxel at 175 mg/m2 in 3 hr intravenous infusion followed by intraperitoneal infusion of carboplatin at AUC of 7.5 as a bolus was administered.
  • We believe that the combination of paclitaxel and carboplatin is one treatment choice for clear cell carcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Middle Aged. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11142173.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Silva EG, Deavers MT, Bodurka DC, Malpica A: Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol; 2006 Jan;25(1):52-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
  • The association of this type of tumor with undifferentiated carcinoma is rare.
  • The endometrioid carcinoma involved the endometrium in 14 cases, the endometrium and 1 or both ovaries in 9 cases, and the ovaries in 2 cases.
  • Undifferentiated carcinoma associated with low-grade endometrioid carcinoma was found at presentation in 19 grade 1 or 2 endometrioid carcinomas: 15 in the endometrium and 5 in the ovary.
  • In one of these cases, undifferentiated carcinoma was found in the endometrium and the ovary.
  • Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver.
  • The undifferentiated carcinoma was composed exclusively of diffuse sheets and solid nests of epithelial cells in l0 cases.
  • Twenty-two patients received additional therapy as follows: chemotherapy (), radiotherapy (), and tamoxifen ().
  • In four cases, the diagnosis was made recently, with short follow-ups of 3 and 4 months.
  • Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma.
  • The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Transformation, Neoplastic. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2006 Jul;25(3):304
  • (PMID = 16306785.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Tohya T, Shimajiri S, Onoda C, Yoshimura T: Complete remission of ovarian endometrioid adenocarcinoma associated with hyperamylasemia and liver metastasis treated by paclitaxel and carboplatin chemotherapy: a case report. Int J Gynecol Cancer; 2004 Mar-Apr;14(2):378-80
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of ovarian endometrioid adenocarcinoma associated with hyperamylasemia and liver metastasis treated by paclitaxel and carboplatin chemotherapy: a case report.
  • Ultrasound examination and CT scan revealed several large solid and cystic intra-abdominal tumors and a metastatic liver tumor.
  • The serum amylase was 600 micro/l (normal value: 60-200 micro/l), and electrophoresis identified isoamylases of the salivary type.
  • A total abdominal hysterectomy with bilateral salpingo-oophorectomy was performed for invasive carcinoma of the left ovary.
  • The histology of the left ovary showed endometrioid adenocarcinoma.
  • The patient received six courses of paclitaxel and carboplatin combination chemotherapy.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Liver Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Hyperamylasemia / etiology. Hysterectomy. Immunohistochemistry. Middle Aged. Ovariectomy. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15086742.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD: Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther; 2006 Jan;5(1):22-7
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
  • PURPOSE: To determine the maximum-tolerated dose (MTD) and toxicity profile of the novel anticancer agent, 2-methoxyestradiol (2ME2) administered orally, in patients with solid tumors.
  • MATERIALS AND METHODS: Twenty patients with refractory solid tumors were enrolled.
  • Tumor biopsies were taken before and after starting the drug to assess for microvessel density by CD 31 and cell proliferation by Ki67 immunohistochemistry.
  • There was one episode of grade 4 angioedema in the 1600 mg bid dose level 38 days into 2ME2 treatment.
  • A patient with clear cell carcinoma of the ovary had a partial response at 1600 mg bid dose level lasting over three years.
  • 2ME2 treatment had no effect on microvessel density (CD31 immunostaining) and cell proliferation (Ki-67 immunostaining).
  • A new formulation of 2ME2 with improved bioavailability is currently being developed.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Estradiol / analogs & derivatives. Maximum Tolerated Dose. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Apoptosis. Capillaries / drug effects. Cell Proliferation / drug effects. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357512.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol
  •  go-up   go-down


11. Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, Pond GR, Dancey JE, Hirte HW: Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol; 2006 Feb;17(2):334-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
  • This phase I study was designed to determine the maximal tolerated dose (MTD), recommended phase 2 dose (RPTD), toxicity profile, pharmacokinetics and antitumor activity of T and UCN-01 in patients with refractory solid tumors.
  • On day 1, following antiemetic prophylaxis with dexamethasone and a serotonin type 3(A) receptor (5HT3) inhibitor, UCN-01 was infused over 3 h, followed by T infused over 30 min.
  • Primary tumor types: ovary/peritoneal (23 patients), colon (three patients), salivary gland (two patients), others (five patients).
  • Most common drug-related AEs were mild (grade 1-2).
  • Best response for 22 evaluable patients was PD (8), SD for at least six cycles (12), PR (1: carcinoma of ovary, dose level 2) and one not assessable.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284058.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-1701
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7BU5H4V94A / 7-hydroxystaurosporine; 7M7YKX2N15 / Topotecan; H88EPA0A3N / Staurosporine
  •  go-up   go-down


12. Dupont J, Bienvenu B, Aghajanian C, Pezzulli S, Sabbatini P, Vongphrachanh P, Chang C, Perkell C, Ng K, Passe S, Breimer L, Zhi J, DeMario M, Spriggs D, Soignet SL: Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors. J Clin Oncol; 2004 Aug 15;22(16):3366-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
  • PATIENTS AND METHODS: Using an accelerated dose-escalation schedule, 48 patients with advanced solid tumors were treated with doses of Ro 31-7453 ranging from 25 to 800 mg/m(2)/d given for 4 consecutive days, every 3 weeks.
  • RESULTS: Forty-five patients completed at least one cycle of therapy.
  • Minor antitumor activity was observed against carcinoma of the lung, breast, pancreas, and ovary.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Indoles / pharmacokinetics. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15310782.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; DNZ11VPY7Q / 1H-pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-
  •  go-up   go-down


13. Fukunaga M, Fujiwara Y, Naito Z: Hepatoid carcinoma with serous component of the fallopian tube: a case report with immunohistochemical and ultrastructural studies. Int J Gynecol Pathol; 2006 Jul;25(3):233-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid carcinoma with serous component of the fallopian tube: a case report with immunohistochemical and ultrastructural studies.
  • A very rare case of hepatoid carcinoma with serous component arising in the fallopian tube of a 79-year-old woman is presented.
  • The tumor was composed of hepatoid carcinoma (90%) and serous carcinoma (10%) components.
  • The hepatoid carcinoma was histologically characterized by a proliferation of round to polygonal cells arranged in a trabecular, tubular, sinusoidal, papillary, or solid pattern.
  • Both components showed an infiltration into the surface of the left ovary, omentum, peritoneum including the pouch of the Douglas, and serosa of the colon.
  • Immunohistochemically, the hepatoid carcinoma was positive for alpha-fetoprotein, polyclonal carcinoembryonic antigen (CEA), hepatocyte paraffin 1, albumin, epithelial membrane antigen, and cytokeratin (CAM5.2).
  • Ultrastructurally, the cytoplasm contained abundant ribosomes, moderate amounts of mitochondria, and rough endoplasmic reticulum that developed into a meshwork and contained mitochondria within it.
  • The association with serous carcinoma indicates mullerian origin rather than germ cell origin.
  • The patient received chemotherapy and was alive without disease at 10 months after surgery.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Fallopian Tube Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratins / analysis. Microscopy, Electron, Transmission. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810059.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 68238-35-7 / Keratins
  •  go-up   go-down


14. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • Tumors were mostly unilateral, cystic, or solid/cystic and ranged in size from 5 to 26 cm (mean 16.2).
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • The latter case had a dermoid cyst in the contralateral ovary.
  • The neoplastic cells were mostly arranged in a solid pattern, nests, or trabeculae.
  • Seven patients were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy.
  • One patient had a bilateral salpingo-oophorectomy with omentectomy and appendectomy followed by chemotherapy; 1 patient had a total abdominal hysterectomy with right salpingo-oophorectomy followed by chemotherapy; one had a bilateral salpingo-oophorectomy followed by chemotherapy, and one had a right salpingo-oophorectomy with appendectomy followed by chemotherapy.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


15. Davidson B: Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog; 2007 Dec;13(3):189-227
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor cells in effusions most frequently originate from primary carcinomas of the ovary, breast, and lung, and from malignant mesothelioma, a native tumor of this anatomic site.
  • Unlike the majority of solid tumors, particularly at the primary site, cancer cells in effusions are not amenable to surgical removal and failure in their eradication is one of the main causes of treatment failure.
  • In recent years, we have studied the biological characteristics of ovarian carcinoma, breast carcinoma, and malignant mesothelioma cells in effusions and compared it to their counterparts in primary tumors and solid metastases.
  • In ovarian carcinoma, several of these molecules are differentially expressed in primary diagnosis (prechemotherapy) and disease recurrence (postchemotherapy) specimens, reflecting the effect of disease progression and chemotherapy, and have different prognostic significance as function of disease progression.
  • The findings presented in this review underscore the need to take into consideration the unique biology of cancer cells in effusions if patient-tailored molecular therapy is to become a successful treatment modality in these malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298385.001).
  • [ISSN] 0893-9675
  • [Journal-full-title] Critical reviews in oncogenesis
  • [ISO-abbreviation] Crit Rev Oncog
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins; 0 / Cell Adhesion Molecules; 0 / Cytokines; 0 / EFN-4 protein, C elegans; 0 / Ephrins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Receptors, Growth Factor
  • [Number-of-references] 167
  •  go-up   go-down


16. Barthomeuf C, Lim S, Iranshahi M, Chollet P: Umbelliprenin from Ferula szowitsiana inhibits the growth of human M4Beu metastatic pigmented malignant melanoma cells through cell-cycle arrest in G1 and induction of caspase-dependent apoptosis. Phytomedicine; 2008 Jan;15(1-2):103-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study we have used the resazurin reduction test and FACS analysis to assess the cytostatic and cytotoxic effect of umbelliprenin from Ferula szowitsiana (Apiaceae) on human solid cancer cells and human primary fibroblasts.
  • We have observed that the cell susceptibility to umbelliprenin decreases in the order M4Beu (metastatic pigmented malignant melanoma)>A549 (nonsmall cell lung carcinoma) approximately PC3 (androgen-resistant prostate carcinoma)>PA1 (ovary teratocarcinoma)>human primary fibroblasts approximately MCF7 (breast adenocarcinoma)>DLD1 (colon adenocarcinoma).
  • The finding that the cytotoxic effect of umbelliprenin is markedly more pronounced in M4Beu cells than in primary fibroblasts, suggests a therapeutic margin.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma / drug therapy. Cell Proliferation / drug effects. Ferula / chemistry. G1 Phase / drug effects. Melanoma / drug therapy. Umbelliferones / pharmacology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Caspases / metabolism. Cell Line, Tumor. Cells, Cultured. Cisplatin / pharmacology. Coumarins / pharmacology. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Fibroblasts / drug effects. Humans. Inhibitory Concentration 50. Plant Roots / chemistry

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689942.001).
  • [ISSN] 0944-7113
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Coumarins; 0 / Umbelliferones; 495-02-3 / aurapten; EC 3.4.22.- / Caspases; MSD8N8A1LQ / umbelliprenin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Isonishi S, Ogura A, Kiyokawa T, Suzuki M, Kunito S, Hirama M, Tachibana T, Ochiai K, Tanaka T: Alpha-fetoprotein (AFP)-producing ovarian tumor in an elderly woman. Int J Clin Oncol; 2009 Feb;14(1):70-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apart from typical yolk sac tumors, ovarian tumors with elevated alfa-fetoprotein (AFP) are uncommon and the differential diagnosis needs to consider the hepatoid pattern of a yolk sac tumor, hepatocellular carcinoma metastatic to the ovary, hepatoid carcinoma, and other epithelial ovarian tumors.
  • We report here an AFP-producing ovarian tumor with uncertain pathological diagnosis, which was extremely responsive to chemotherapy.
  • Microscopically, the tumor was characterized by a hepatoid carcinomatous component composed of solid sheets of large eosinophilic cells with pleomorphic nuclei.
  • The patient was treated postoperatively with three cycles of chemotherapy consisting of bleomycin, etoposide, and cisplatin; with this regimen, serum AFP decreased to 16 ng/ml from 12 600 ng/ml just before the initiation of chemotherapy.
  • [MeSH-major] Carcinoma / secretion. Ovarian Neoplasms / secretion. alpha-Fetoproteins / secretion
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Omentum / surgery. Ovariectomy. Rectum / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Pathol Jpn. 1992 May;42(5):372-5 [1378991.001]
  • [Cites] Am J Surg Pathol. 1996 Sep;20(9):1056-66 [8764742.001]
  • [Cites] Arch Pathol Lab Med. 1984 Sep;108(9):710-2 [6205636.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2355-68 [7139531.001]
  • [Cites] Am J Surg Pathol. 1987 Oct;11(10):767-78 [3661822.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(2):182-9 [2456275.001]
  • [Cites] Am J Surg Pathol. 1993 Jan;17(1):85-90 [7680545.001]
  • [Cites] Cancer. 1987 Dec 1;60(11):2775-84 [2445465.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1296-9 [3679203.001]
  • (PMID = 19225928.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Bidus MA, Webb JC, Seidman JD, Rose GS, Boice CR, Elkas JC: Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol; 2006 Jul;102(1):5-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bevacizumab has demonstrated activity against a variety of solid tumors, including ovarian carcinoma.
  • CASES: One patient each with recurrent, refractory well-differentiated serous-endometrioid ovarian carcinoma, micropapillary serous carcinoma of the ovary, and primary peritoneal micropapillary serous carcinoma were treated with single agent bevacizumab (15 mg/kg [DOSAGE ERROR CORRECTED] intravenously every 3 weeks).
  • CONCLUSION: Bevacizumab may have significant activity against well-differentiated ovarian carcinoma and micropapillary serous carcinomas of the ovary or peritoneum.
  • Since these tumors are generally indolent and not responsive to adjuvant therapy, further investigation is warranted.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Gynecol Oncol. 2007 May;105(2):559. dosage error in text
  • (PMID = 16697451.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


19. Lee KR, Nucci MR: Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis. Int J Gynecol Pathol; 2003 Jan;22(1):42-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis.
  • We report four cases of mucinous ovarian carcinoma in which the cells were entirely or almost entirely endocervical-like.
  • Two patients had bilateral tumors confined to the ovaries at initial staging; both also had synchronous endometrial carcinomas of the mucinous type.
  • In one of the latter cases a mullerian (endocervical-like) mucinous borderline tumor (MMBT) of the opposite ovary had been removed 5 years earlier, and in this case and two other cases the ovarian carcinomas had foci resembling MMBT, suggesting that they may be an invasive counterpart to these tumors.
  • The six tumors ranged from 4 to 19 cm; five were grossly cystic with papillary or solid areas, and one was entirely solid.
  • Endometriosis was present in residual ovarian tissue adjacent to four tumors in three patients and had marked epithelial proliferation in three.
  • All patients were treated postoperatively with chemotherapy and were without clinical recurrence with follow-up intervals of 8 months, 1.2 years, 2.9 years, and 3.8 years.
  • By immunohistochemical analysis the neoplastic epithelium was positive for estrogen and progesterone receptor proteins, vimentin, and cytokeratin 7, and negative or only focally positive for carcinoembryonic antigen and cytokeratin 20, a profile that differs from that of the usual mucinous ovarian carcinoma and is supportive of a mullerian derivation.
  • To better understand their clinicopathologic features and pathogenesis, this uncommon variant should be separated from the usual type in future studies of mucinous carcinomas of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometriosis / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12496697.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


20. Tamaskar I, Mekhail T, Dreicer R, Olencki T, Roman S, Elson P, Bukowski RM: Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. Invest New Drugs; 2008 Dec;26(6):553-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Temozolomide is an alkylating agent which crosses the blood brain barrier and has demonstrated antitumor activity against a broad range of tumor types, including malignant glioma, melanoma, non small cell lung cancer and carcinoma of the ovary and colon.
  • A Phase I trial was conducted to determine the toxicity of this combination in refractory solid tumor patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Survival Rate. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1998 Oct;25(5 Suppl 12):32-4 [9865710.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1377-82 [17416857.001]
  • [Cites] Cancer Treat Rev. 1997 Jan;23 (1):35-61 [9189180.001]
  • [Cites] Invest New Drugs. 1994;12(3):169-82 [7896535.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):98-103 [12468349.001]
  • [Cites] Clin Lung Cancer. 2002 May;3(4):254-8 [14662033.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4845-52 [1680023.001]
  • [Cites] Br J Cancer. 1992 Feb;65(2):287-91 [1739631.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1455-61 [18300256.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8389-95 [16293869.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):90-6 [15598944.001]
  • [Cites] Cancer Res. 1998 Oct 1 ;58(19):4363-7 [9766665.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):309-17 [10037179.001]
  • [Cites] N Engl J Med. 1995 Apr 13;332(15):1004-14 [7885406.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):203-7 [12675312.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):5846-52 [3664486.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):910-3 [7707118.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):420-5 [11786569.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):1022-30 [10576660.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):1996-2004 [15558071.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] Anticancer Drugs. 1997 Jan;8(1):92-7 [9147618.001]
  • [Cites] Clin Cancer Res. 1997 Jul;3(7):1093-100 [9815788.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):61-5 [15719277.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):742-7 [10762746.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1212-9 [10715290.001]
  • (PMID = 18626572.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


21. Izydore RA, Zhang Y, Zhou X, Warren AE, Wheaton JR, Hall IH: The cytotoxicity of 1-(1-phenylalkylideneamino)-2,4-azetidinediones and their mode of action in human and murine tumor cells. Anticancer Res; 2001 Jan-Feb;21(1A):157-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 1-(1-phenylalkylideneamino)-2,4-azetidinediones are potent cytotoxic agents against the growth of human and murine leukemias, lymphoma, and suspended HeLa uterine carcinoma.
  • In cell lines cultured from solid human tumors, the agents were more selective with only a few agents demonstrating significant activity against the growth of HCT-8 ileum adenocarcinoma, Saos-2 osteosarcoma, KB nasopharynx, MCF-7 breast effusion, and ovary 1-A9 carcinoma A mode of action study in murine L1210 lymphoid leukemia cells showed that the agents inhibited DNA and RNA syntheses after 60 min.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Azetidines / pharmacology. Leukemia L1210 / drug therapy
  • [MeSH-minor] Animals. DNA Replication / drug effects. Drug Screening Assays, Antitumor. HL-60 Cells. HeLa Cells. Humans. Mice. Purines / metabolism. Transcription, Genetic / drug effects. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11299729.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Azetidines; 0 / Purines
  •  go-up   go-down






Advertisement